To include your compound in the COVID-19 Resource Center, submit it here.

FX006: Phase II hold

Flexion said FDA placed a clinical hold on a double-blind, placebo-controlled, U.S. Phase IIb trial of FX006 following an infection in 1 patient's knee joint after

Read the full 263 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE